Loading...
XNAS
AGIO
Market cap2.10bUSD
Aug 05, Last price  
36.21USD
1D
0.14%
1Q
28.31%
Jan 2017
-13.23%
IPO
30.35%
Name

Agios Pharmaceuticals Inc

Chart & Performance

D1W1MN
No data to show
P/E
3.12
P/S
57.64
EPS
11.60
Div Yield, %
—
Shrs. gr., 5y
-0.71%
Rev. gr., 5y
-20.91%
Revenues
36m
+36.07%
21,837,00025,106,00025,548,00065,358,00059,119,00069,892,00043,011,00094,387,000117,912,000203,196,000014,240,00026,823,00036,498,000
Net income
674m
P
-23,706,000-20,102,000-39,407,000-53,504,000-117,732,000-198,471,000-314,670,000-346,028,000-396,611,000-335,218,0001,604,715,000-74,555,000-352,088,000673,725,000
CFO
-390m
L+31.68%
-15,219,000-49,548,000-56,400,000-59,353,000-76,949,00038,562,000-285,232,000-304,421,000-370,622,000-290,759,000-407,320,000-309,478,000-296,062,000-389,841,000

Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
URL
https://www.agios.com/
IPO date
Jul 24, 2013
Employees
389
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
36,498
36.07%
26,823
88.36%
14,240
 
Cost of revenue
305,451
298,407
281,614
Unusual Expense (Income)
NOPBT
(268,953)
(271,584)
(267,374)
NOPBT Margin
Operating Taxes
44,244
(157,246)
Tax Rate
NOPAT
(313,197)
(271,584)
(110,128)
Net income
673,725
-291.35%
(352,088)
372.25%
(74,555)
-104.65%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,433
2,681
BB yield
-0.44%
-0.17%
Debt
Debt current
33,562
30,016
13,663
Long-term debt
97,195
185,972
157,655
Deferred revenue
Other long-term liabilities
880
(55,832)
3,279
Net debt
(762,953)
(590,375)
(1,239,549)
Cash flow
Cash from operating activities
(389,841)
(296,062)
(309,478)
CAPEX
(1,685)
(999)
(4,881)
Cash from investing activities
363,441
239,575
243,261
Cash from financing activities
14,442
5,433
2,350
FCF
(320,940)
(271,540)
(94,701)
Balance
Cash
893,710
776,928
1,096,993
Long term investments
29,435
313,874
Excess cash
891,885
805,022
1,410,155
Stockholders' equity
(150,369)
(823,018)
(483,025)
Invested Capital
1,782,755
1,722,197
1,672,777
ROIC
ROCE
EV
Common stock shares outstanding
57,889
55,651
54,789
Price
32.86
47.55%
22.27
-20.69%
28.08
-14.57%
Market cap
1,902,241
53.49%
1,239,359
-19.44%
1,538,487
-22.57%
EV
1,139,288
648,984
298,938
EBITDA
(263,300)
(264,961)
(258,810)
EV/EBITDA
Interest
12,793
Interest/NOPBT